850 related articles for article (PubMed ID: 18324353)
41. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies.
Epstein J; Sanderson IR; Macdonald TT
Br J Nutr; 2010 Jun; 103(11):1545-57. PubMed ID: 20100380
[TBL] [Abstract][Full Text] [Related]
42. Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review.
Soleimani V; Sahebkar A; Hosseinzadeh H
Phytother Res; 2018 Jun; 32(6):985-995. PubMed ID: 29480523
[TBL] [Abstract][Full Text] [Related]
43. Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of Glioblastoma.
Luthra PM; Lal N
Eur J Med Chem; 2016 Feb; 109():23-35. PubMed ID: 26748069
[TBL] [Abstract][Full Text] [Related]
44. Curcumin--from molecule to biological function.
Esatbeyoglu T; Huebbe P; Ernst IM; Chin D; Wagner AE; Rimbach G
Angew Chem Int Ed Engl; 2012 May; 51(22):5308-32. PubMed ID: 22566109
[TBL] [Abstract][Full Text] [Related]
45. Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives.
Tsuda T
Food Funct; 2018 Feb; 9(2):705-714. PubMed ID: 29206254
[TBL] [Abstract][Full Text] [Related]
46. Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer.
Almatroodi SA; Syed MA; Rahmani AH
Recent Pat Anticancer Drug Discov; 2021; 16(1):3-29. PubMed ID: 33143616
[TBL] [Abstract][Full Text] [Related]
47. Curcumin, a component of turmeric: from farm to pharmacy.
Gupta SC; Kismali G; Aggarwal BB
Biofactors; 2013; 39(1):2-13. PubMed ID: 23339055
[TBL] [Abstract][Full Text] [Related]
48. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma.
Sun ZJ; Chen G; Zhang W; Hu X; Liu Y; Zhou Q; Zhu LX; Zhao YF
Mol Pharmacol; 2011 Jan; 79(1):106-18. PubMed ID: 20959361
[TBL] [Abstract][Full Text] [Related]
49. Curcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cells.
Waghela BN; Sharma A; Dhumale S; Pandey SM; Pathak C
PLoS One; 2015; 10(2):e0117526. PubMed ID: 25692854
[TBL] [Abstract][Full Text] [Related]
50. A Comprehensive Review on Physiological Effects of Curcumin.
Ahsan R; Arshad M; Khushtar M; Ahmad MA; Muazzam M; Akhter MS; Gupta G; Muzahid M
Drug Res (Stuttg); 2020 Oct; 70(10):441-447. PubMed ID: 32746480
[TBL] [Abstract][Full Text] [Related]
51. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis.
Kim JH; Gupta SC; Park B; Yadav VR; Aggarwal BB
Mol Nutr Food Res; 2012 Mar; 56(3):454-65. PubMed ID: 22147524
[TBL] [Abstract][Full Text] [Related]
52. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity.
Biswas SK; McClure D; Jimenez LA; Megson IL; Rahman I
Antioxid Redox Signal; 2005; 7(1-2):32-41. PubMed ID: 15650394
[TBL] [Abstract][Full Text] [Related]
53. Delivery of curcumin and medicinal effects of the copper(II)-curcumin complexes.
Leung MH; Harada T; Kee TW
Curr Pharm Des; 2013; 19(11):2070-83. PubMed ID: 23116313
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties.
Olivera A; Moore TW; Hu F; Brown AP; Sun A; Liotta DC; Snyder JP; Yoon Y; Shim H; Marcus AI; Miller AH; Pace TW
Int Immunopharmacol; 2012 Feb; 12(2):368-77. PubMed ID: 22197802
[TBL] [Abstract][Full Text] [Related]
55. [Neuroprotective effects of curcumin].
Li Y; Wang P
Zhongguo Zhong Yao Za Zhi; 2009 Dec; 34(24):3173-5. PubMed ID: 20352992
[TBL] [Abstract][Full Text] [Related]
56. Curcumin and its Potential for Systemic Targeting of Inflamm-Aging and Metabolic Reprogramming in Cancer.
Kujundžić RN; Stepanić V; Milković L; Gašparović AČ; Tomljanović M; Trošelj KG
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30857125
[TBL] [Abstract][Full Text] [Related]
57. Biological activities of Curcuma longa L.
Araújo CC; Leon LL
Mem Inst Oswaldo Cruz; 2001 Jul; 96(5):723-8. PubMed ID: 11500779
[TBL] [Abstract][Full Text] [Related]
58. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials.
Shehzad A; Wahid F; Lee YS
Arch Pharm (Weinheim); 2010 Sep; 343(9):489-99. PubMed ID: 20726007
[TBL] [Abstract][Full Text] [Related]
59. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications.
Bar-Sela G; Epelbaum R; Schaffer M
Curr Med Chem; 2010; 17(3):190-7. PubMed ID: 20214562
[TBL] [Abstract][Full Text] [Related]
60. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research.
Jurenka JS
Altern Med Rev; 2009 Jun; 14(2):141-53. PubMed ID: 19594223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
